Takeda: Edarbyclor demonstrates statistically superior blood-pressure reductions

DEERFIELD, Ill. — A Takeda drug designed to treat hypertension was statistically superior to a competing drug in reducing systolic blood pressure among patients in a late-stage clinical trial.

Takeda said a fixed dose combination of its drug Edarbyclor (azilsartan medoxomil and chlorthalidone) in the 40/25-mg strength, when compared with fixed-dose combination of olmesartan medoxomil-hydrochlorothiazide in the 40/25-mg strength, more effectively lowered blood pressure at each hour of the 24-hour period between doses (reduction of 42.5 mm Hg from baseline versus 37.1 mm Hg from baseline). The results, demonstrated in a 12-week, head-to-head, phase-3 study, were published online in Hypertension, a journal of the American Heart Association.

"Hypertension and its impact on cardiovascular health have long been studied; the goal of this particular study was to determine whether a fixed-dose combination of a well-established yet underutilized diuretic paired with a new angiotensin II receptor blocker would provide an effective option to help control hypertension," said study co-author Michael Weber, professor of medicine at the State University of New York Downstate College of Medicine. "The data showed that Edarbyclor exhibited superior blood-pressure reductions, compared to a commonly-used combination treatment."

Interested in this topic? Sign up for our weekly Collaborative Care e-newsletter.